HHarle + # 4

Docket No. 38345-174995

ASSISTANT COMMISSIONER FOR PATENTS

p. D.C. 20231

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Sheet _1_ of _1

In the application of: Han-Mo KOO et al.

Application Serial No.: 09/942,940

Filing Date:

August 31, 2001

For:

INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAY: A SELECTIVE THERAPEUTIC STRATEGY

AGAINST MELANOMA

Examiner: (Unassigned) Group Art Unit: 1614

U.S. PATENT DOCUMENTS Document (If appropriate) Examiner's Filing Date Ref# Initials Number **Date** <u>Name</u> 5,591,631 1997 1. 2. 5,677,274 1997 Leppla-FOREIGN PATENT DOCUMENTS

Examiner's Ref# Initials

Document

Number

Date

Country

If appropriate) Filing Date

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Examiner's

Ref#	<u>initiais/</u>	
3.	ork.	Alessi, D.R. et al., J Biol Chem 270:27489-27494 (1995)
4.	. />	Dudley, D.T. et al., Proc Nat'l Acad Sci USA 92:7686-7689 (1995)
5.		Sivaraman, VS et al., J. Clin. Invest. 99:1478-483 (1997)
6.		Englaro, W. et al. J Biol Chem 273:9966-9970 (1998)
7.		Duesbery, NS et al., CMLS Cell. Mol. Life Sci. 55:1599-1609 (1999)
8.		Licato, L.L. et al. Digestive Diseases and Sciences 43, 1454-1464 (1998))
9		Vitale, G. et al., Biochem Biophys Res Comm 248:706-711 (1998)
(1)		Mandell, JW et al., Am. J. Pathol. 153:1411-23 (1998)
$(1\overline{1})$		Roussel, M.F., Adv Canc Res, 74:1-24 1998)
12.		Duésbery, N.S. et al., Science 280:734-737 (1998)
13.		Salh, B et al., Anticancer Res. 19(1B):731-40 (1999)
14.		Sebolt-Leopold, JS et al., Nature Med. 5: 810-816 (1999)
15.		Collen, P. Curr Opin Chem Biol 3:459-465 (1999)
16.		Hoshino, R. et al., Oncogene 18:813-822 (1999)
17.	4	Chin, L. et al. (Nature 400:468-472 (1999)
		n = 0 411/c n = /28/03

RECEIVED

Attalut # 7

ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 2023 TRADEN

APR 1 6 2003

TECH CENTER 1600/2900

Docket No. 38345-174995

PATENT

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) Sheet _1_ of _1

In the application of:

Han-Mo KOO et al.

U.S. Application Serial No.:

09/942,940

Filing Date:

August 31, 2001

Group Art Unit: 1642

Examiner: Minh-Tam Davis

For:

INHIBITION OF MITOGEN-ACTIVATED

PROTEIN KINASE (MAPK) PATHWAY: A SELECTIVE THERAPEUTIC STRATEGY

AGAINST MELANOMA

U.S. PATENT DOCUMENTS

Examiner's Initials

Document

Number <u>Date</u> Name

(If appropriate)

Filing Date

FOREIGN PATENT DOCUMENTS

Examiner's

Document

<u>Date</u>

If appropriate)

Ref#

Ref#

Initials

<u>Number</u>

Country

Filing Date

1. 2.

WO 99/50439 WO 02/076496

10/7/99 10/3/02 **WIPO WIPO**

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Examiner's

Ref#

Initials

4.

5.

3.

W. Englaro et al., "Inhibition of the mitogen-activated protein kinase

pathway triggers B16 melanoma cell differentiation", Journal of Biological Chemistry, Vol. 273, No. 16, pages 9966-9970 Duesbery, N.S. et al., "Suppression of Ras-Mediated Transformation And Inhibition of Tumor Growth and Angiogenesis By Anthrax Lethal Factor, A Proteolytic Inhibitor of Multiple MEK Pathways",

Proceedings of the National Academy of Sciences, of USA, National Academy of Science, Vol. 98, No. March 27, 2001, pages 4089-4094 H.M. Koo et al., "Apoptosis and Melanogenesis in Human Melanoma Cells Induced by Anthrax Lethal Factor Inactivation of Mitogen-Activated Protein Kinase Kinase", Proceedings of the National Academy of Sciences, of USA, Vol. 99, No. 5, March 5, 2002, pages

3052-3057

Ex M. T. DAVIS,

05/27/03